natgillin/translations-raw huggingface dataset:
The pharmaceutical composition for use of claim 8, wherein the cancer or tumor is selected from the group consisting of glioblastoma, ductal or intraductal breast carcinoma, non-small cell lung carcinomas, ovarian carcinomas, prostate cancer, and squamous cell carcinoma of the head and neck. 
Farmaceutski pripravak za primjenu prema patentnom zahtjevu 8, naznačen time, što je rak ili tumor odabran iz skupine koja se sastoji od glioblastoma, duktalnog ili intraduktalnog karcinoma dojke, nemikrocelularnih karcinoma pluća, karcinoma jajnika, raka prostate i karcinoma skvamoznih stanica glave 1 vrata.
A compound according to claim 1 that is (4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone, or an enantiomer, hydrate, solvate, or pharmaceutically acceptable salt thereof. 
Spoj u skladu sa zahtjevom 1, naznačen time, da je (4-ciklopropil-piperazin-1-il)(4-morfolin-4-ilmetil-fenil)- metanon ili njegov enantiomer, hidrat, solvat ili farmaceutski prihvatljiva sol.
The organic solvent was removed by evaporation, and the aqueous phase was extracted with ethyl acetate. 
Organsko otapalo se ukloni uparavanjem, a vodena faza se ekstrahira s etil acetatom.
o Spin at 20,000 rpm for 17 minutes at 4°C. 
Vrti na 20.000 okr/min tijekom 17 minuta na 4*C.
6 this upper capsule ejector 25 is in an retracted position. 
U položaju kao što je prikazan na slici 6, ta gornja naprava za izbacivanje čahure 25 se nalazi na uvučenom položaju.
where either, using Bruker D8 Advance instrument, irradiation: Cu Ka at 30 kV, 40 mA, variable slit V12 mm, scan range 2 - 40° (2 theta value), scan rate 0.3 s per step or, using XDS2000 by Scintag instrument, irradiation: Cu Ka at 45 kV, 40 mA, divergence slice 3 mm and 2 mm, measuring slice: 0.3 mm and 0.2 mm, chopper 0.02 grd, scan time: 6 minutes with 3 minutes per frame, scan range: 2° - 35° or 40° (2 theta value) and scan rate 0.5°/min (2 theta value) can be used for the XRPD. 
XDS2000 Scintagov uređaj, zračenje: Cu Ka na 45 kV, 40 mA, prorez za divergenciju 3 mm i 2 mm, mjerni prorez: 0.3 mm i 0.2 mm, sjeckač (engl. chopper) 0.02 grd, vrijeme analize: 6 minuta s 3 minute po okviru, raspon analize: 2* - 35% ili 40" (2 theta vrijednost) i brzina analize 0.5%/min (2 theta vrijednost).
Competitive radioligand binding assays with membrane preparations are performed in Millipore 96-well filtration plates with GF/C membrane filters which are precoated with 200 ul of 0.1% polyethylenimine (Sigma, St. Louis. 
Ispitivanja vezanja kompetitivnog radioliganda na membranskim preparatima provedena su na pločama za filtriranje s 96 jažica Millipore s GF/C membranskim filtrima prethodno obloženim s 200 ul 0,1 % polietilenimina (Sigma, St. Louis.
contacting a compound of Formula 12, with an enzyme to yield the compound of Formula 11 and a compound of Formula 13, 
> s enzimom, kako bi se dobilo spoj Formule 3, ili njegovu sol, i spoj Formule 5 R!
an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 8; 
(a) spektar difrakcije X-zraka praha (XRPD), isti kao što je prikazan na Slici 2;
The crude product is used in the next step. 
Sirovi produkt upotrijebi se u sljedećem koraku.
Ammonium sulphite caramel is specified having an A280/560 of less than 50. 
Amonij sulfit karamela je specifična po tome što ima A2g0;56o manji od 50.
Process for the preparation of the compound 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide of formula (I): or a pharmaceutically acceptable salt thereof, comprising the following steps: 
Upotreba spoja kako je prijavljen u patentnim zahtjevima 1 - 3 kao međuprodukt u sintezi 6-(7-((1- aminociklopropil)metoksi)-6-metoksikinolin-4-iloksi)-N-metil-1-naftamida (D) ili odgovarajuće farmaceutski prihvatljive soli.
The method according to claim 44 or 45, wherein the host cell is selected to produce an antibody molecule composition having at least one of the following further glycosylation characteristics: 
Postupak u skladu s patentnim zahtjevom 44 ili 45, naznačen time što se stanicu domaćina tako bira da proizvodi pripravak s molekulom protutijela koja ima najmanje jednu od sljedećih daljnjih značajki glikoziliranja:
An expression vector encoding a nucleic acid according to Claim 4. 
Nukleinska kiselina prema Zahtjevu 4 koja je DNK, cDNK, PNK, CNK, RNK ili kombinacija navedenih.
<10 (ppb) A process for removing pesticides from Ginkgo biloba extracts comprising, the following steps: 
Postupak uklanjanja pesticida iz ekstrakta Ginko biloba, naznačen time da se ekstrakt dobiven uobičajenim postupkom podvrgava sljedećim koracima: a)
The electronic controller according to claim 21, wherein said electronic controller is implemented as a PII controller. 
Uređaj (40) sukladno zahtjevu 12, 13 ili 14 ili elektronički kontroler (50) sukladno zahtjevu 15 ili 16, pri čemu je navedeni kontroler implementiran kao PII kontroler.
at least one 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol of formula (I), optionally in form of one of its stereoisomers, in particular an enantiomer or a diastereomer, a racemate or in form of a mixture of its stereoisomers, in particular enantiomers and/or diastereomers in any mixing ratio, or any corresponding acid addition salt thereof, and at least one antiepileptic selected from the group consisting of topiramate, lamotrigine, carbamazepine, lacosamide, levetiracetam and retigabin. 
(a) barem jedan 3-(3-Dimetilamino-1-etil-2-metil-propil)-fenol sa formulom (I), il proizvoljno u obliku jednog od njegovih stereoizomera, naročito enantiomera ili diastereomera, racemata ili u obliku smjese njegovih stereoizomera, naročito enantiomera i/ili diastereomera u bilo kojem omjeru miješanja, ili bilo koja odgovarajuća kisela adicijska sol, te (b) barem jedno antiepileptičko sredstvo odabrano iz skupine koja sadrži topiramat, lamotrigin, karbamazepin, lakozamid, levetiracetam i retigabin.
A fusion protein according to claim 1, wherein: X is a signal peptide or wherein the signal peptide is a protein selected from the group consisting of F1gI, NadA and pelB. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je X signalni peptid iz proteina koji se bira iz skupine koju čine Flgl, NadA i pelB.
The compound of Formula Xa 
Spoj, naznačen time, da ima Formulu Xa [image]
Use of (a) a compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient, which is used in combination with (b) at least one other antitumor compound, for the production of an antitumor agent. 
Upotreba (a) spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, kao aktivni sastojak, kojeg se upotrebljava u kombinaciji s (b) najmanje još jednim antitumorskim spojem, naznačena time što su spoj formule [I] i dodatni antitumorski spoj namijenjeni proizvodnji antitumorskog sredstva.
The pharmaceutical dosage formulation of claim 5, wherein the glidant is selected from the group consisting of talc, cornstarch, and silica. 
je izabran iz skupine koju čine vodik, C1-4alkil, hidroksi(C1-4)alkil i fenil(C1-6)alkoksi(C1-4)alkil;
The composition according to claim 1, comprising about 2 mg to about 4 mg of buprenorphine. 
Pripravak sukladno patentnom zahtjevu 1 sadrži 2 mg buprenorfina.
The method of claim 1, wherein the solvent is dichloromethane or chloroform, or wherein the non-solvent is methanol or ethanol, or both. 
PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 10, gdje je otapalo diklorometan ili kloroform i ne-otapalo je metanol ili etanol.
is independently phenyl substituted with 0-3 R6, pyridinyl substituted with 0-2 R6, pyrazinyl substituted with 0-2 R6, pyrimidinyl substituted with 0-2 R6, thiazolyl substituted with 0-2 R6, and 
R' je nezavisno fenil supstituiran sa 0-3 R*, piridinil supstituiran sa 0-2 R, pirazinil supstituiran sa 0-2 R, pirimidinil supstituiran sa 0-2 R", tiazolil supstituiran sa 0-2 R,
providing a second reaction vessel (12) containing a negative electrode and a liquid electrolytic medium comprising a mixture of water and carbon dioxide; 
(b) osiguravanje druge reakcijske posude (12) koja sadrži negativnu elektrodu (32) i tekući elektrolitički medij koji sadrži smjesu vode u ugljikovog dioksida;
wherein the polymorph exhibits in an X-ray powder diffractogram using CuKa2 radiation at least reflections within the two ranges selected from 15.4-15.8 and 
xHcl () naznačen time da polimorf iskazuje u difraktogramu X-zraka na prahu korištenjem CuKa; zračenja refleksije barem unutar dva raspona koji su odabrani od
An antibody that specifically binds to an N-terminal epitope of AB, for use in the treatment or prophylaxis of a disease characterized by amyloid deposits in the brain in the patient, in at least one of a first and a second regime, wherein a measurement of ApoE4 copy number is used to select from the different regimes. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 4, za primjenu u liječenju ili profilaksi bolesti koju karakteriziraju amiloidne naslage u mozgu pacijenta, prema najmanje jednom od prvog i drugog režima, pri čemu se za izbor režima koristi određivanje broja kopija ApoE4.
The compound according to any one of claims 1 to 3, characterized in that R4 has the following formula: wherein X0 represents OH or NR9R10 and m is 1 or 2. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time da arilna skupina jest fenilna skupina te heterociklil je zasićen, nezasićen ili aromatski prsten s 5 ili 6 članova koji sadrži 1 ili 2 dušikova atoma.
A process of claim 11 or claim 12 wherein the solid phase has a substance attached to it covalently. 
Postupak sukladno patentnom zahtjevu 11 ili patentnom zahtjevu 12 naznačen time, da čvrsta faza sadrži tvar vezanu na njega kovalentno.
Strips of the coatings were extracted with n-hexane. 
Trake prevlaka su ekstrahirane s n-heksanom.
An L-proline co-crystal of a compound of formula (I-X) 
Kokristal L-prolina spoja formule (I-X) [image]
adding the aqueous solution onto the alcohol mixture and mixing (123), 
- > dodavanja vodene otopine u alkoholnu smjesu i miješanje (123),
the composition comprises sodium ions, potassium ions, phosphate ions, chloride ions and polysorbate-80; 
(vii) farmaceutski sastav obuhvaća natrijeve ione, kalijeve ione, fosfatne ione, kloridne ione, i polisorbat 80;
Use of a nucleic acid being IKBKE mRNA, cDNA, or a complement thereof for diagnosing endometrial cancer in vitro. 
Upotreba nukleinske kiseline koja je početnica za P4HB, naznačena time što je navedena nukleinska kiselina namijenjena dijagnosticiranju raka endometrija in vitro.
A pharmaceutical composition as claimed in claims 5 or 6, which comprises one or more, additional agents selected from the group more additional agents selected from the group consisting of Alzhemed, vitamin E, ginkolide, donepezil, nvastigmine, tacrine, galantamine, memantine, NS-2330, ibutamoren mesylate, capromoreline, minocycline and rifampicine 
Farmaceutski pripravak prema zahtjevima 5 ili 6, naznačen time da sadrži jedno ili više, dodatnih sredstava odabranih iz skupine koja sadrži Alzhemed, vitamin E, ginkolid, donepezil, rivastigmin, takrin, galantamin, memantin, NS-2330, ibutamoren mesilat, kapromorelin, minociklin i rifampicin. HR P20130721 T1
The compound according to claim 1, which is a compound represented by the formula wherein R1 is a cyclohexyl optionally substituted by a C1-6 alkoxy optionally substituted by a hydroxy, and R2 is a C1-6 alkyl. 
Spoj prema zahtjevu 1, naznačen time, da je taj spoj predstavljen formulom [image] gdje je C3-8cikloalkil opcijski supstituiran s C1-6alkoksi koji je opcijski supstituiran s 1) atomom halogena, 2) cijano, 3) hidroksi ili 4) C1-6alkoksi koji je opcijski supstituiran s atomom halogena,
Such situations could arise when the bottle is to be replaced by a new bottle or in case of breakdown or maintenance of parts of the apparatus. 
Takove situacije se mogu pojaviti kad se bocu mora zamijeniti s novom bocom ili u slučaju prekida ili održavanja dijelova aparata.
In some embodiments, the aqueous base in step b) above comprises sodium hydroxide (NaOH) and an alcohol, and the conditions suitable for forming the compound of formula I comprise a temperature of between about 40° C. about 80° C. and a pH of about 9 to about 10.5. In some embodiments, the alcohol includes, but is not limited to, methanol, ethanol, iso-propanol, butanol, t-butanol, pentanol. In some embodiments, the aqueous base in step b) above comprises sodium hydroxide (NaOH) and isopropyl alcohol (IPA), and the conditions suitable for forming the compound of formula I comprise a temperature of about 80° C. and a pH of about 10.2. 
Postupak prema zahtjevu 1, naznačen time da vodena baza u dijelu b) sadrži natrijev hidroksid i alkohol, i pogodni uvjeti za nastanak spoja s formulom I obuhvaćaju temperaturu od između oko 40 "€ oko 80 "C i pH od oko 8 do oko 10.5; poželjno pri čemu: vodena baza u koraku b) sadrži natrijev hidroksid (NaOH) i izopropil alkohol (IPA), te pogodni uvjeti za nastanak spoja s formulom I obuhvaćaju temperaturu od oko 80 *C i pH od oko 9. Spoj s formulom III: o" | VIDIĆ
A combination for use according to any one of claims 1 to 10 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
Uporaba sukladno bilo kojem od patentnih zahtjeva 11, 19 120, naznačena time, da se koristi za liječenje bolesnika koji pate od prijašnjeg srčanog stanja ili stanja koje može biti pogoršano tahikardijom.
VL1 is a first immunoglobulin light chain variable domain; 
VLi je varijabilna domena prvog lakog imunoglobulinskog lanca;
A molecule comprising an antibody Fab fragment that specifically binds human AB peptide, wherein the antibody fragment comprises a light chain variable region of SEQ ID NO: 1 and a heavy chain variable region of SEQ ID NO: 2, and wherein said antibody fragment is covalently attached to a polyethylene glycol molecule at the cysteine at amino acid 56 of SEQ ID NO: 2, wherein the polyethylene glycol molecule has a molecular weight of 0.5 kD to 30 kD. 
Molekula, naznačena time što sadrži fragment Fab protutijela koji se specifično veže na ljudski peptid AB, gdje fragment protutijela sadrži varijabilno područje lakog lanca sa SEQ ID NO: 1 i varijabilno područje teškog lanca sa SEQ ID NO: 2, gdje je navedeni fragment protutijela kovalentno vezan na molekulu polietilen-glikola na cisteinu na aminokiselinskom položaju 56 sa SEQ ID NO: 2, te gdje molekula polietilen-glikola ima molekulsku težinu od 0,5 kDa do 30 kDa.
The unit dose of claim 1 or 2, wherein the 0.5ml of an aqueous pharmaceutical solution has a pH of 5.5-7.0. 
Jedinična doza prema patentnom zahtjevu 1 ili 2, naznačena time, da 0,5 ml vodene farmaceutske otopine ima pH od 5,5-7,0.
the outer shell (OS) is then placed in a cooled environment; 
- - vanjsko kučište (SK) se zatim stavlja u ohlađenu ambijentalnu sredinu;
In another embodiment, the present invention relates to a chiral auxiliary (4S)-4-benzyl-1,3-thiazolidin-2-one which would be of versatile utility for asymmetric synthesis. 
PATENTNI ZAHTJEVI 5 1. Pomoćno kiralno sredstvo, naznačeno time, da je to spoj (4S)-4-benzil-1,3- tiazolidin-2-on.
The compound of claim 9 for use in treating hepatitis C infections further comprising using at least one additional compound having therapeutic benefits for HCV wherein the compound is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors. 
Smjesa prema zahtjevu 9, naznačena time što se koristi za liječenje zaraza virusom hepatitisa C i dalje sadrži barem jedan dodatni spoj s terapijskim učinkom na HCV pri čemu se taj spoj izabire iz skupine koja obuhvaća interferone, ciklosporine, interleukine, inhibitore metaloproteaze HCV-a, inhibitore serin proteaze HCV-a, inhibitore polimeraze HCV-a, inhibitore helikaze HCV-a, inhibitore proteina NS4B HCV-a, inhibitore ulaska HCV-a, inhibitore nakupljanja HCV-a, inhibitore izlaska HCV-a, inhibitore proteina NS5A HCV-a, inhibitore proteina NS5B HCV-a i inhibitore replikacije HCV-a
Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in different primary packaging systems (such as capsules and cartridges of for example gelatine or blisters of for example laminated aluminium foil), for use in an inhaler or insufflator. 
Suhi praškasti pripravci za lokalnu primjenu inhalacijom u pluća mogu se izraditi, primjerice, u različitim primarnim sustavima za pakiranje (poput kapsula i patrona, izrađenih primjerice od želatine, odnosno blister-pakiranja od laminirane aluminijske folije) za uporabu u inhalatoru ili insuflatoru.
Use of a DNA base associated with a cell free nucleosome as a biomarker in a body fluid sample for the diagnosis of cancer, cardiomyopathy, systemic lupus erythematosus, colitis, chronic obstructive pulmonary disorder, Crohn's disease and rheumatoid arthritis, wherein the DNA base is selected from: 5-methylcytosine or 5-hydroxymethylcytosine. 
PATENTNI ZAHTJEVI Upotreba baze DNK koja je povezana s nukleosomom bez stanica kao biomarkerom u uzorku tjelesne tekućine za dijagnozu raka, kardiomiopatije, sistemskog eritematoznog lupusa, kolitisa, kroničnog opstruktivnog plućnog poremećaja, Crohnove bolesti i reumatoidnog artritisa, naznačena time što je baza DNK odabrana od: 5- metilcitozina ili 5-hidroksimetilcitozina.
drying a spent ruthenium-based catalyst carried on aluminum oxide at 100-150° C. in a nitrogen atmosphere for 1-2 hours, calcining the spent ruthenium-based catalyst carried on aluminum oxide at 300-500° C. for 2-4 hours, cooling the spent ruthenium-based catalyst carried on aluminum oxide to room temperature, and grinding the spent ruthenium-based catalyst carried on aluminum oxide into black powder comprising ruthenium oxide; 
1) sušenje otpadnog katalizatora aluminijevog oksida napunjenog s rutenijem na 100-150*C u atmosferi dušika tijekom 1-2 sata, kalciniranje otpadnog katalizatora aluminijevog oksida napunjenog s rutenijem na 300-500"C tijekom 2-4 sata, hlađenje otpadnog katalizatora aluminijevog oksida napunjenog s rutenijem na sobnu temperaturu, te mljevenje otpadnog katalizatora aluminijevog oksida napunjenog s rutenijem u crni prah koji sadrži rutenijev oksid;
subjecting the compound of formula (5) when W represents =O, or compound of formula (6) to ring-opening, removal of any P1 protecting groups, and optionally removing any additional protecting groups to give a compound of formula (7). 
HR P20100287 TI da bi se dobio spoj formule (5) i e) podvrgavanje spoja formule (6) otvaranju prstena, uklanjanju bilo koje zaštitne grupe P! i opcijski uklanjanje bilo kojih dodatnih zaštitnih grupa da bi se dobio spoj formule (7).
The method according to claim 1, wherein the compound is administered in the form of a medicament, wherein the medicament comprises the compound in an amount of from 0.1 ng to 10 mg based on the total weight of the medicament. 
Spoj za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je spoj kao sastojak lijeka u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 meg, najbolje od 100 ng do 100 ug.
The pharmaceutical composition for use as claimed in any of Claims 1 to 7, which is for anti-arthritis. 
Farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, da treba djelovati protiv artritisa.
The method of claim 14, wherein the cancer is selected from prostate cancer, non-small cell lung cancer, ovarian cancer, bladder cancer and gastric cancer. 
Uporaba prema zahtjevu 17, naznačena time da rak je odabran od raka prostate, raka pluća ne-malih stanica, raka jajnika, raka mjehura i raka želuca.
or a pharmaceutically acceptable salt thereof, with a base under suitable conditions to form a compound of formula (8): 
Q <I ili njegove farmaceutski prihvatljive soli, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
Paragraph 37. A method of treating a subject with Gaucher disease, comprising administering to the subject an effective amount of a first compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof in combination with an effective amount of a second therapeutic agent that is effective for treating Gaucher disease. 
: ili njegova farmaceutski prihvatljiva sol, za proizvodnju lijeka naznačeno time da je za upotrebu za liječenje Gaucherove bolesti, pri čemu navedeno liječenje obuhvaća davanje učinkovite količine prvog terapijskog sredstva u kombinaciji s učinkovitom količinom drugog terapijskog sredstva koje je korisno za liječenje Gaucherove bolesti.
A compound as claimed in claims 1 or 6, or a pharmaceutically acceptable salt or ester thereof, or a pharmaceutical composition as claimed in claim 2, wherein R1 is Cl. 
Spoj prema zahtjevima 1 ili 6, ili njegova farmaceutski prihvatljiva sol ili njegov farmaceutski prihvatljiv ester, ili farmaceutski sastav prema zahtjevu 2, naznačen(a) time, da RI je CI.
The compound of Claim 9, where R1 is 3-fluoro, 4-fluoro, 5-fluoro, 5-trifluoromethyl, or 6-fluoro. 
Spoj u skladu s patentnim zahtjevom 9, naznačen time, da R1 je 3-fluoro, 4- fluoroo, 5-fluoro, 5-trifluorometil ili6-fluoro.
The compound according to claim 1, wherein m denotes 1 or 2. The compound according to claim 1 selected from the group of: 
Lijek prema zahtjevu 1, naznačen time što sadrži spoj odabran iz skupine koju čine:
Method according to claim 2, wherein the conversion coating is made by spraying the strip with an aqueous solution of 5 to 50 g/l, preferably 15 to 25 g/l, of a first initial solution comprising < 1 wt.-% diammonium dimolybdate and 5 to 10 wt.-% hexafluorozirconic acid, and 0.01 to 0.3 g/l, preferably 0.1 to 0.3 g/l, of a second initial solution comprising 10 to 25 wt.-% ammonium fluoride and 10 to 25 wt.-% ammonium hydrogen difluoride, and 0 to 2 g/l, preferably 0.05 to 0.2 g/l, of a third initial solution comprising 25 wt.-% polycarboxylic acid in water. 
Postupak prema zahtjevu 2, naznačen time, da se konverzijski sloj izvodi putem sprejanja trake s vodenom otopinom od 5 do 50 g/l, poželjno od 15 do 25 g/l prve početne otopine koja sadrži < 1 masenog % diamonij-dimolibdata i od 5 do 10 masenih % heksafluorocirkonijske kiseline, i od 0,01 do 0,3 g/l, poželjno od 0,1 do 0,3 g/l druge početne otopine koja sadrži od 10 do 25 masenih % amonij-fluorida i od 10 do 25 masenih % amonij-vodikovog difluorida, te od 0 do 2 g/l, poželjno od 0,05 do 0,2 g/l treće početne otopine koja sadrži 25 masenih % polikarboksilne kiseline u vodi.
is individually and independently selected from the group consisting of basic amino acids; and wherein said cyclic peptide consists of at least 16 and of at most 25 amino acids and is functionally active as a binding partner for (auto-)antibodies against the second extracellular loop (ECII) of B1-adrenergic receptor (B1-AR); 
y je aminokiselina koja nije Cys, i gdje navedeni ciklički peptid se sastoji od najmanje 16, a najviše 25 aminokiselina i ima aminokiselinski slijed Asp-Xxx1-Xxx4-Arg-Arg-Cys-Xxx3-Asn-Asp-Pro-Lys (SEQ ID NO. 45); ili Glu-Ser-Asp-Xxx1-Xxx4-Arg-Arg-Cys-Xxx3-Asn-Asp-Pro-Lys (SEQ ID NO. 46), gdje su Xxx1, Xxx3 i Xxx4 aminokiseline koja nisu Cys, i gdje navedeni ciklički peptid može smanjiti protutijelom inducirano aktiviranje B1-adrenergičkog receptora (B1-AR);
It is known to provide a cap to occlude the nozzle of an inhaler in order to prevent the entrance of dust and dirt. 
Poznato je da se na inhalator može postaviti zatvarač koji okružuje raspršivač inhalatora da se spriječi ulazak prašine i nečistoća.